8Fisher B, Brown AM, Dimotrov NV, et al, Two months of doxoruhicin-cyclophosphamid with and without interval reinduction therapy compared with six months of cyclophosphamid, methotrexate and fluorouracil in positive node of breast cancer patients with tamoxifen nonresponsive tumors: results from NSABPB 15.J Clin Oncol, 1990,8(9):1483
9Fisher B, Jeong JH, Anderson S, et al. Treatment of axillary lymphnode negative, estrogen receptor negative breast cancer;update findings from National Surgical Adjuvant Breast and Bowel Project Clinical Trials. J Natl Cancer Inst, 2004,96(24):1823
2[2]Levine MN, Bramwell VH, Pritchavd KI, et al. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer[J] :J Clin Oncol, 1998; 16: 2651-2658.
3[3]Holmes FA, Walters RS, Theriault RL, et al. Phase Ⅱ trail of paclitaxel,an active drug in the treatmet of metastatic breast cancer[J] .J Natl Cancer Inst, 1991; 83: 1796.
4[4]Clifford A, Hudis and pamela N, Munster. High-Dose therapy for breast cancer[J] .Seminars in Oncology, 1999,26: 35-47.
5[6]Norton L.Evolving concepts in the systemic drug therapy of breast cancer[J] .Semin Oncol, 1997;24(Suppl 10): 10-3-10-10.
6[7]Harris J, Morrowm,Norton L.Malignant tumors of the breast[M] .In: Pevita VT Jr, Hellman S, Rosenberg SA, Principhes & Practiec of Onclogy. 5th ed.philadelphia, PA: Lippincott-Raven, 1997:1557-1616.
10Hamett P, Buck M, Beale P, et al. Phase II study of gemeitabine and oxaliplatin in patients with recurrent ovarian cancer:an Australian and New Zealand Gynaecological Oncology Group study[ J]. lnt J Gy- necolCancer, 2007, 17 (2) : 359-366.
